Share chart Enveric Biosciences, Inc.
Extended chart
Simple chart
About
Enveric Biosciences, Inc., биотехнологическая компания, занимается разработкой низкомолекулярных терапевтических средств для лечения тревоги, депрессии и зависимостей. Его ведущей программой является EB-373, активный метаболит псилоцибина, который проходит первую фазу клинических испытаний для лечения тревожных расстройств; ЭВМ-301 для лечения психического здоровья; и конъюгат EV104 CBD + целекоксиб для лечения остеоартрита.
More details| Выручка | 0.0399 |
|---|---|
| EBITDA | -0.0041 |
| P/BV | 1.21 |
| EV/EBITDA | -4.27 |
| P/S | 0.3219 |
| Цена ао | 1.06 |
| P/E | 2.15 |
| ISIN | US29405E2081 |
| Число акций ао | 0.00216 млрд |
| Сайт | https://www.enveric.com |
| Див.доход ао | 0 |
| Дивиденд ао | 18489.5 |
| Валюта | usd |
| IPO date | 2015-06-24 |
| Sector | Health Care |
| Industry | Biotechnology |
| Валюта отчета | usd |
| Change price per day: | +2.67% (0.412) |
|---|---|
| Change price per week: | +1.93% (0.415) |
| Change price per month: | -15.57% (0.501) |
| Change price per 3 month: | -17.86% (0.515) |
| Change price per half year: | -54.9% (0.938) |
| Change price per year: | -79.95% (2.11) |
| Change price per 3 year: | -76.76% (1.82) |
| Change price per 5 year: | +63.89% (0.2581) |
| Change price per year to date: | -70.32% (1.425) |
|
|
Underestimation
|
Efficiency
|
|||||||||||||||||||||||||||||||||||||
Dividends
|
Debt
|
Growth impulse
|
|||||||||||||||||||||||||||||||||||||
| Institutions | Volume | Share, % |
|---|---|---|
| AdvisorShares Investments, LLC | 100429 | 4.83 |
| Blackrock Inc. | 29578 | 1.42 |
| Tower Research Capital LLC (TRC) | 14129 | 0.68 |
| Susquehanna International Group, LLP | 12481 | 0.6 |
| Vanguard Group Inc | 12125 | 0.58 |
| UBS Group AG | 5318 | 0.26 |
| Acadian Asset Management. LLC | 4559 | 0.22 |
| Group One Trading, L.P. | 273 | 0.01 |
| Royal Bank of Canada | 228 | 0.01 |
| Bank of America Corporation | 100 | 0 |
| Head | Job title | Payment | Year of birth |
|---|---|---|---|
| Dr. Joseph Edward Tucker Ph.D. | CEO & Director | 825.94k | 1969 (55 years) |
| Dr. Peter J. Facchini Ph.D. | Chief Innovation Officer | 332.38k | 1964 (60 years) |
| Mr. Kevin M. Coveney CPA | Chief Financial Officer | 1964 (60 years) |
Address: United States, Naples. FL, 4851 Tamiami Trail N - open in Google maps, open in Yandex maps
Website: https://www.enveric.com
Website: https://www.enveric.com
